Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE

Scott Ayton, Noel G. Faux, Ashley I. Bush, Michael W. Weiner, Paul Aisen, Ronald C. Petersen, Clifford R. Jack, William Jagust, John Q. Trojanowki, Arthur W. Toga, Laurel Beckett, Robert C. Green, Andrew J. Saykin, John C. Morris, Leslie M. Shaw, Zaven S. Khachaturian, Greg Sorensen, Lew Kuller, Marc Raichle, Steven M. Paul, Peter J. Davies, Howard Fillit, Franz Hefti, Davie Holtzman, Marek-Marsel Mesulam, William Z. Potter, Peter J. Snyder, Adam J. Schwartz, Tom Montine, Ronald G. Thomas, Michael Donohue, Sarah Walter, Devon Gessert, Tamie Sather, Gus Jiminez, Danielle Harvey, Matt A. Bernstein, Nick C. Fox, Paul M. Thompson, Norbert Schuff, Bret Borowski, Jeff Gunter, Matthew L. Senjem, Prashanthi Vemuri, David Jones, Kejal Kantarci, Chad Ward, Robert A. Koeppe, Norm Foster, Eric M. Reiman, Kewei Chen, Chester A. Mathis, Susan Landau, Nigel J. Cairns, Erin Householder, Lisa Taylor‐Reinwald, Virginia Lee, Magdalena Korecka, Michal Figurski, Karen Crawford, Scott Neu, Tatiana Foroud, Steven Potkin, Li Shen, Kelley Faber, Sungeun Kim, Kwangsik Nho, Leon J. Thal, Neil Buckholtz, Marylyn Albert, Richard Frank, John Hsiao, Jeffrey Kaye, Joseph F. Quinn, Betty Lind, Raina Carter, Sara Dolen, Lon S. Schneider, Sonia Pawluczyk, Mauricio Beccera, Liberty Teodoro, Bryan M. Spann, James B. Brewer, Helen Vanderswag, Adam Fleisher, Judith L. Heidebrink, Joanne Lord, Sara S. Mason, Colleen S. Albers, David S. Knopman, Kris Johnson, Rachelle S. Doody, Javier Villanueva‐Meyer, Munir Chowdhury, Susan Rountree, Mimi Dang, Yaakov Stern, Lawrence S. Honig, Karen L. Bell, Beau M. AncesNature Communications 2015 · DOI

Abstract: Brain iron elevation is implicated in Alzheimer's disease (AD) pathogenesis, but the impact of iron on disease outcomes has not been previously explored in a longitudinal study. Ferritin is the major iron storage protein of the body; by using cerebrospinal fluid (CSF) levels of ferritin as an index, we explored whether brain iron status impacts longitudinal outcomes in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. We show that baseline CSF ferritin levels were negatively associated with cognitive performance over 7 years in 91 cognitively normal, 144 mild cognitive impairment (MCI) and 67 AD subjects, and predicted MCI conversion to AD. Ferritin was strongly associated with CSF apolipoprotein E levels and was elevated by the Alzheimer's risk allele, APOE-ɛ4. These findings reveal that elevated brain iron adversely impacts on AD progression, and introduce brain iron elevation as a possible mechanism for APOE-ɛ4 being the major genetic risk factor for AD.

Introduction

While iron accumulation in the brain has long been implicated in the pathogenesis of Alzheimer’s disease (AD) due to its role in oxidative stress, longitudinal evidence linking iron status to clinical progression was largely missing. Most existing studies were cross-sectional or focused on end-stage pathology. This study sought to determine if brain iron status, indexed by cerebrospinal fluid (CSF) ferritin, could predict cognitive decline, brain atrophy, and the conversion from Mild Cognitive Impairment (MCI) to AD over a multi-year period.

Methodology

The study utilized data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), analyzing a subset of 302 subjects: 91 cognitively normal (CN) individuals, 144 subjects with MCI, and 67 subjects with AD. Researchers measured baseline levels of CSF ferritin, apolipoprotein E (ApoE), tau, and amyloid-beta ($A\beta_{1-42}$). To analyze the data, they employed mixed-effects linear models (MELM) to track annual cognitive scores and brain volume changes via MRI over 6–7 years, alongside Cox proportional hazards to model the risk and timing of conversion from MCI to AD.

Results and The APOE Connection

A key insight from the study is that ferritin acts as a "trait variable." Unlike tau or amyloid, which are associated with the rate of cognitive deterioration, ferritin levels were associated with a constant downward shift in cognitive performance. This suggests that high brain iron lowers "cognitive reserve," making individuals reach the threshold for a clinical AD diagnosis much sooner.

Crucially, the study identified a strong relationship between the $APOE$ genotype and iron levels. $APOE-\epsilon4$ carriers (the high-risk group) exhibited significantly higher CSF ferritin levels and lower CSF ApoE levels. This suggests that the $APOE-\epsilon4$ allele may increase AD risk specifically by promoting iron retention in the brain.

Figure 4: Relationship between APOE genotype, CSF ApoE, and CSF ferritin levels. (a) Correlation between CSF ApoE and ferritin. (b) Higher ferritin in ε4 carriers. (c) Lower ApoE in ε4 carriers.

Quantitatively, high baseline ferritin ($>7.2$ ng/ml) was associated with a ~3-point poorer ADAS-Cog13 score compared to low levels. An increase in baseline ferritin by one interquartile range increased the odds of converting from MCI to AD (Odds Ratio: 2.32), and a one standard deviation increase was associated with a 9.5-month earlier conversion to AD. Furthermore, higher CSF ferritin independently predicted faster rates of hippocampal shrinkage and lateral ventricular enlargement.

Discussion and Future Directions

The authors hypothesize that $APOE-\epsilon4$ carriers have lower levels of CSF ApoE, which is involved in trafficking lipoproteins that help clear intracellular iron. Reduced clearance leads to iron accumulation, increased oxidative stress, and accelerated neurodegeneration.

While baseline CSF ferritin levels were not significantly higher in AD patients compared to controls—likely because CSF reflects global brain iron rather than regional sequestration—ferritin's independent predictive power significantly improved models of disease progression. These findings support the investigation of iron-lowering therapies, such as chelation, in clinical trials. The authors estimate that lowering CSF ferritin could potentially delay MCI-to-AD conversion by up to 3 years.

Summary updated

Abstract

Brain iron elevation is implicated in Alzheimer's disease (AD) pathogenesis, but the impact of iron on disease outcomes has not been previously explored in a longitudinal study. Ferritin is the major iron storage protein of the body; by using cerebrospinal fluid (CSF) levels of ferritin as an index, we explored whether brain iron status impacts longitudinal outcomes in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. We show that baseline CSF ferritin levels were negatively associated with cognitive performance over 7 years in 91 cognitively normal, 144 mild cognitive impairment (MCI) and 67 AD subjects, and predicted MCI conversion to AD. Ferritin was strongly associated with CSF apolipoprotein E levels and was elevated by the Alzheimer's risk allele, APOE-ɛ4. These findings reveal that elevated brain iron adversely impacts on AD progression, and introduce brain iron elevation as a possible mechanism for APOE-ɛ4 being the major genetic risk factor for AD.
BibTeX
@inproceedings{ayton2015ferritin,
  author = {Scott Ayton and Noel G. Faux and Ashley I. Bush and Michael W. Weiner and Paul Aisen and Ronald C. Petersen and Clifford R. Jack and William Jagust and John Q. Trojanowki and Arthur W. Toga and Laurel Beckett and Robert C. Green and Andrew J. Saykin and John C. Morris and Leslie M. Shaw and Zaven S. Khachaturian and Greg Sorensen and Lew Kuller and Marc Raichle and Steven M. Paul and Peter J. Davies and Howard Fillit and Franz Hefti and Davie Holtzman and Marek-Marsel Mesulam and William Z. Potter and Peter J. Snyder and Adam J. Schwartz and Tom Montine and Ronald G. Thomas and Michael Donohue and Sarah Walter and Devon Gessert and Tamie Sather and Gus Jiminez and Danielle Harvey and Matt A. Bernstein and Nick C. Fox and Paul M. Thompson and Norbert Schuff and Bret Borowski and Jeff Gunter and Matthew L. Senjem and Prashanthi Vemuri and David Jones and Kejal Kantarci and Chad Ward and Robert A. Koeppe and Norm Foster and Eric M. Reiman and Kewei Chen and Chester A. Mathis and Susan Landau and Nigel J. Cairns and Erin Householder and Lisa Taylor‐Reinwald and Virginia Lee and Magdalena Korecka and Michal Figurski and Karen Crawford and Scott Neu and Tatiana Foroud and Steven Potkin and Li Shen and Kelley Faber and Sungeun Kim and Kwangsik Nho and Leon J. Thal and Neil Buckholtz and Marylyn Albert and Richard Frank and John Hsiao and Jeffrey Kaye and Joseph F. Quinn and Betty Lind and Raina Carter and Sara Dolen and Lon S. Schneider and Sonia Pawluczyk and Mauricio Beccera and Liberty Teodoro and Bryan M. Spann and James B. Brewer and Helen Vanderswag and Adam Fleisher and Judith L. Heidebrink and Joanne Lord and Sara S. Mason and Colleen S. Albers and David S. Knopman and Kris Johnson and Rachelle S. Doody and Javier Villanueva‐Meyer and Munir Chowdhury and Susan Rountree and Mimi Dang and Yaakov Stern and Lawrence S. Honig and Karen L. Bell and Beau M. Ances},
  title = {{Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE}},
  booktitle = {Nature Communications},
  year = {2015},
  doi = {10.1038/ncomms7760},
}
Figure